SLC6A19-IN-4

SLC6A19-IN-4 is an allosteric-competitive and orally active B⁰AT1 inhibitor. SLC6A19-IN-4 inhibits both human and mouse B⁰AT1b> with IC50 values of 513 nM and 295 nM, respectively. SLC6A19-IN-4 exhibits excellent metabolic stability. SLC6A19-IN-4 significantly increases urinary phenylalanine (Phe) excretion and reduces plasma Phe levels through dual inhibition of B⁰AT1 in both the intestine (reducing absorption) and kidney (promoting excretion) in vivo. SLC6A19-IN-4 can be used for phenylketonuria (PKU) and other disorders involving SLC6-family transporters research[1].